FDA Recalls MG217 Eczema Cream Over Staph Risk

Eczema cream recalled over risk of 'life-threatening' staph infection – Image for illustrative purposes only (Image credits: Unsplash)

The Food and Drug Administration announced the recall of a widely available eczema treatment after laboratory tests revealed contamination with Staphylococcus aureus. Pharmacal, the Jackson, Wisconsin-based manufacturer, is withdrawing its MG217 Multi-symptom Treatment Cream & Skin Protectant from distribution. The action follows confirmation that the product poses a serious infection hazard to users.

Scope of the Recall

The affected cream is marketed for eczema relief and general skin protection. It was sold through retail outlets and online channels across the United States. Pharmacal initiated the voluntary recall after internal testing identified the bacterial presence in certain batches.

Distribution records show the product reached pharmacies, supermarkets, and direct-to-consumer sellers. No specific lot numbers have been released publicly yet, so regulators advise checking all units on hand. The company has halted further shipments while the investigation continues.

Potential Health Consequences

Staphylococcus aureus can trigger skin infections that range from mild irritation to deep tissue damage. In vulnerable individuals the bacteria may enter the bloodstream and produce life-threatening complications. The FDA classified the risk level as significant enough to warrant immediate removal from shelves.

People with compromised immune systems, open wounds, or existing skin conditions face heightened exposure. Medical experts note that prompt treatment with antibiotics usually resolves most cases, yet delays can allow the infection to spread rapidly. The recall aims to prevent additional exposures before symptoms appear.

Company Response and Next Steps

Pharmacal stated it is cooperating fully with federal investigators to determine how the contamination occurred. The firm has begun notifying distributors and retailers to pull remaining inventory. Consumers who purchased the cream are urged to stop using it immediately and return it to the point of sale.

The FDA continues to monitor reports of adverse events linked to the product. Additional guidance on disposal and refunds is expected in the coming days. Pharmacal has established a customer service line for questions about specific purchases.

Protecting Yourself Going Forward

Anyone who has used the recalled cream and develops redness, swelling, or pus at the application site should seek medical attention without delay. Health officials recommend keeping receipts or packaging for verification during returns. Checking expiration dates on similar products can help avoid future surprises.

Broader awareness of product recalls remains essential for household safety. Regular review of FDA announcements provides an early warning system for contaminated goods. Pharmacal and regulators will release updated information as testing results become available.